First International Bank & Trust Increases Stock Holdings in Johnson & Johnson (NYSE:JNJ)

First International Bank & Trust lifted its holdings in shares of Johnson & Johnson (NYSE:JNJGet Rating) by 104.2% during the third quarter, HoldingsChannel.com reports. The fund owned 4,406 shares of the company’s stock after purchasing an additional 2,248 shares during the quarter. Johnson & Johnson makes up 0.3% of First International Bank & Trust’s holdings, making the stock its 27th largest position. First International Bank & Trust’s holdings in Johnson & Johnson were worth $720,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of JNJ. Price T Rowe Associates Inc. MD lifted its holdings in shares of Johnson & Johnson by 18.9% during the second quarter. Price T Rowe Associates Inc. MD now owns 24,622,795 shares of the company’s stock worth $4,370,793,000 after purchasing an additional 3,912,430 shares during the period. FMR LLC lifted its holdings in shares of Johnson & Johnson by 20.8% during the second quarter. FMR LLC now owns 18,725,049 shares of the company’s stock worth $3,323,883,000 after purchasing an additional 3,229,032 shares during the period. GQG Partners LLC lifted its holdings in shares of Johnson & Johnson by 64.4% during the first quarter. GQG Partners LLC now owns 6,501,761 shares of the company’s stock worth $1,151,931,000 after purchasing an additional 2,547,378 shares during the period. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main lifted its holdings in shares of Johnson & Johnson by 52.2% during the second quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 6,102,999 shares of the company’s stock worth $1,083,329,000 after purchasing an additional 2,093,392 shares during the period. Finally, Arrowstreet Capital Limited Partnership lifted its holdings in shares of Johnson & Johnson by 37.2% during the first quarter. Arrowstreet Capital Limited Partnership now owns 6,653,610 shares of the company’s stock worth $1,179,219,000 after purchasing an additional 1,805,632 shares during the period. 67.94% of the stock is currently owned by hedge funds and other institutional investors.

Johnson & Johnson Trading Down 0.3 %

Johnson & Johnson stock opened at $168.31 on Tuesday. The stock has a market cap of $440.04 billion, a PE ratio of 23.44, a P/E/G ratio of 3.21 and a beta of 0.56. The stock has a 50-day moving average price of $176.07 and a 200 day moving average price of $171.13. Johnson & Johnson has a 52 week low of $155.72 and a 52 week high of $186.69. The company has a current ratio of 1.43, a quick ratio of 1.18 and a debt-to-equity ratio of 0.37.

Johnson & Johnson Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 7th. Investors of record on Tuesday, February 21st will be given a dividend of $1.13 per share. This represents a $4.52 dividend on an annualized basis and a yield of 2.69%. The ex-dividend date of this dividend is Friday, February 17th. Johnson & Johnson’s dividend payout ratio is presently 62.95%.

Wall Street Analysts Forecast Growth

A number of research firms have commented on JNJ. Barclays began coverage on Johnson & Johnson in a report on Monday, October 17th. They issued an “equal weight” rating and a $175.00 target price for the company. Atlantic Securities reduced their target price on Johnson & Johnson from $165.00 to $160.00 and set a “neutral” rating for the company in a report on Wednesday, October 19th. Raymond James reduced their target price on Johnson & Johnson from $192.00 to $185.00 and set an “outperform” rating for the company in a report on Wednesday, October 19th. Morgan Stanley reduced their target price on Johnson & Johnson from $178.00 to $176.00 and set an “equal weight” rating for the company in a report on Tuesday, December 6th. Finally, Citigroup raised their target price on Johnson & Johnson from $198.00 to $205.00 and gave the company a “buy” rating in a report on Monday, December 12th. Seven equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $181.75.

Insider Buying and Selling

In related news, EVP Jennifer L. Taubert sold 76,923 shares of Johnson & Johnson stock in a transaction dated Tuesday, November 22nd. The stock was sold at an average price of $176.78, for a total transaction of $13,598,447.94. Following the completion of the sale, the executive vice president now owns 126,456 shares in the company, valued at approximately $22,354,891.68. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In other Johnson & Johnson news, CFO Joseph J. Wolk sold 14,781 shares of Johnson & Johnson stock in a transaction dated Tuesday, December 13th. The stock was sold at an average price of $179.60, for a total value of $2,654,667.60. Following the completion of the sale, the chief financial officer now owns 35,812 shares in the company, valued at approximately $6,431,835.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Jennifer L. Taubert sold 76,923 shares of Johnson & Johnson stock in a transaction dated Tuesday, November 22nd. The shares were sold at an average price of $176.78, for a total value of $13,598,447.94. Following the completion of the sale, the executive vice president now owns 126,456 shares of the company’s stock, valued at approximately $22,354,891.68. The disclosure for this sale can be found here. In the last quarter, insiders sold 233,611 shares of company stock worth $40,960,735. 0.35% of the stock is owned by corporate insiders.

Johnson & Johnson Profile

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health, and wound care markets.

Featured Articles

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.